While the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) and Valsartan Antihypertensive Long‐term Use Evaluation (VALUE) studies have suggested a reduction in new onset AF with AT1 receptor blockade (Wachtell et al. 2005; Schmieder et al. 2008), other trials involving ACE inhibitors (e.g., Hansson et al. 1999a,b; Salehian et al. 2007) or ARB (e.g., Yusuf et al. 2008) have not revealed any benefit of RAAS inhibition in patients with primary hypertension. The gene discussed is AGTR1; the disease is hypertensive disorder.